医学博士，博士研究生导师、河南省特聘教授、河南省科技创新杰出人才、河南省卫生科技领军人才。目前担任河南省转化医学中心常务副主任、细胞治疗河南省工程实验室主任、河南省肿瘤免疫治疗工程技术研究中心主任、河南省肿瘤免疫治疗重点实验室主任、郑州市生物治疗重点实验室主任等。拥有二十多年的生物细胞治疗经验，并拥有10余年的欧洲、美国学习与工作经历。主持或参与过十余项国家973项目、欧盟科研计划项目、美国癌症研究所、美国癌症协会、美国NIH等基金项目。目前主持国家自然科学基金3项，省部级基金数十项。在国际著名期刊包括Blood, J Clin Invest, Cancer Res, J Immunol, Int J Cancer, Eur J Immunol，Tissue Antigens, J Immunol Immunother和PLoS Pathogen等发表高影响力SCI论文数十篇。多次被邀请做大会或分会发言，在国内的学术大会做邀请发言数十次。获得2项国际专利及1项国内专利。目前是欧洲免疫学会、美国癌症学会、美国免疫家学会、美国科学促进会、国际生物治疗专业委员会会员，担任中华医学生物免疫学会会长、中国研究型医院学会生物治疗学专业委员会副主任委员、中国生物治疗专业委员会常委、中国免疫学会科普专业委员会常委、中华医学会组织损伤和修复分会委员、中国医药质量管理协会细胞治疗质量控制与研究专业委员会副主任委员、中国医药生物技术协会医药生物技术临床应用专业委员会委员、河南省免疫学会副理事长、河南省免疫学会细胞治疗专业委员会主任委员、河南省免疫学会干细胞专业委员会常务副主任委员、河南省抗癌协会肿瘤生物治疗专业委员会副主任委员、河南省细胞生物学会干细胞专业委员会副主任委员、河南省医学会神经修复学专科分会副主任委员、河南省老年学会常务理事、《中华实用诊断与治疗杂志》学术指导委员会委员、《中国肿瘤生物治疗杂志》编委、《郑州大学学报（医学版）》编委、《中国医药导报》杂志编委，及10余种国内外学术期刊的特约审稿人。

发表文章：

1.Zhang T，Cao L, Xie J, Wang L, Zhang Y*. Efficiency of CD-19 Chimeric Antigen Receptor-Modified T Cells for treatment of B Cell Malignancies in Phase I Clinical Trials: a Meta Analysis. Oncotarget, 2015 accepted.

2.Yang L#, Wang F#, Wang L, Huang L, Wang J, Zhang B, Zhang Y*. CD163+ tumor-associated macrophage is a prognostic biomarker and is associated with therapeutic effect on malignant pleural effusion of lung cancer patients. Oncotarget, 2015, 6(12):10592-10603.

3.Liu J, Li F, Ping Y, Wang L, Chen X, Wang D, Gao Q, Zhao S, Li B, Kalinski P, Thorne S, Zhang B, Zhang Y*. Local production of the chemokines C CL5 and CXCL10 attracts CD8+ T lymphocytes into esophageal squamous cell carcinoma. Oncotarget, 2015, accepted.

4.Zhao X, Zhang Z, Li H, Huang J, Yang S, Xie T, Huang L, Yue D, Xu L, Wang L, Zhang W*, Zhang Y*. Cytokine Induced Killer Cells-Based Immunotherapies in Patients with Different Stages of Renal Cell Carcinoma. Cancer Letters, 2015, 362(2):192-198.

5.Liu J, Li F, Wang L, Chen X, Wang D, Cao L, Ping Y, Zhao S, Li B, Thorne S, Zhang B, Kalinski P, Zhang Y*. CTL- versus Treg lymphocytes-attracting chemokines, CCL4 and CCL20, are strong reciprocal predictive markers for survival of patients with esophageal squamous cell carcinoma. Brit J Cancer, 2015, accepted.

6.Wang F#, Yang L#, Gao Q, Huang L, Wang L, Wang J, Wang S, Zhang B, Zhang Y*. CD163+CD14+ macrophages, a novel diagnostic biomarker for malignant pleural effusion. Cancer Immunol Immun, 2015, 64(8):965-976.

7.Yue D, Zhang Z, Li J, Chen X, Ping Y, Liu S, Shi X, Li L, Wang L, Huang L, Zhang B, Sun Y, Zhang Y*. Transforming growth factor-beta1 promotes the migration and invasion of sphere-forming stem-like cell subpopulations in esophageal cancer. Exp Cell Res, 2015, pii: S0014-4827(15)30016-1. DOI:10.1016/j.yexcr.2015.06.007.

8.Zhang Z, Wang L, Luo Z, Zhao X, Huang J, Li H, Yang S, Zhao X, Zhang L, Li L, Wang F, Huang L, Zhang Y*. Efficacy and safety of cord blood derived cytokine-induced killer cells in treatment of patients with malignancies. Cytotherapy, 2015, 17(8):1130-1138.

9.Wang M, Li J, Wang L, Chen X, Zhang Z, Yue D, Ping Y, Shi X, Huang L, Zhang T, Yang L, Zhao Y, Ma X, Li D, Fan Z, Zhao L, Tang Z, Zhai W, Zhang B, Zhang Y*. Combined cancer testis antigens enhanced prediction accuracy for prognosis of patients with hepatocellular carcinoma. Int J Clin Exp Patho, 2015, accepted.

10.Wang M, Li J, Ping Y, Li Z, Wang L, Guo Q, Zhang Z, Yue D, Wang F, Zhang T, Islam MS, Zhang Y*. Host HLA-A*02 allele is associated with the response to pegylated interferon and ribavirin in patients with chronic hepatitis C infection. Arch Virol, 2015, 160(4):1043-1054.

11.Li S#, Yue D#, Chen X, Wang L, Li J, Ping Y, Gao Q, Wang D, Zhang T, Li F, Yang L, Huang L, Zhang Y*. Epigenetic regulation of CD271, a potential cancer stem cell marker associated with chemoresistance and metastatic capacity. Oncol Rep, 2015, 33(1):425-432.

12.Zhang Z, Zhao X, Zhang T, Wang L, Yang L, Huang L, Li F, Liu J, Yue D, Wang Fei, Li J , Guan F, Xu Y, Zhang B, Zhang Y*. Phenotypic characterization and antitumor effects of the cytokine-induced killer cells derived from cord blood. Cytotherapy, 2015, 17(1):86-97. IF: 3.1.

13.Zhang T, Cao L, Zhang Z, Yue D, Ping Y, Li H, Huang L, Zhang Y*. Review of cancer immunology: application of chimeric antigen receptor T cells and programmed death 1/Programmed death-ligand 1 antibody. Cancer Translational Medicine, 2015, 1(2):43.

14.Wang M, Zhang Y, Li Z, Zhang H, Zhang Z, Yue D, Zhou R, Li X, Wu S, Li J. Hepatitis C virus (HCV) genotype 2a has a better virologic response to antiviral therapy than HCV genotype 1b. Int J Clin Exp Med. 2015, 8(5):7446-7456.

15.Chen S, Zhang Y, Kuzel TM, Zhang B. Regulating Tumor Myeloid-Derived Suppressor Cells by MicroRNAs. Cancer Cell Microenviron, 2015, 2(1), pii: e637.

16.Chen S, Wang L, Fan J, Ye C, Dominguez D, Zhang Y, Curiel TJ, Fang D, Kuzel TM, Zhang B. Host miR155 Promotes Tumor Growth through a Myeloid-Derived Suppressor Cell-Dependent Mechanism. Cancer Res, 2015, 75(3):519-531.

17.Zhang Z, Wang LP, Zhao XL, Wang F, Huang L, Wang M, Chen XF, Li H, Zhang Y*. Pseudomonas aeruginosa injection enhanced antitumor cytotoxicity of cytokine-induced killer cells derived from cord blood. Biomed Pharmacother, 2014, 68(8):1057-1063.

18.Yue D, Fan Q, Chen X, Li F, Wang L, Huang L, Dong W, Chen X, Zhang Z, Liu J, Wang F, Wang M, Zhang B, Zhang Y*. Epigenetic inactivation of SPINT2 is associated with tumor suppressive function in esophageal squmous cell carcinoma. Exp Cell Res, 2014, 322(1): 149-158.

19.Li JY, Duan XF, Wang LP, Xu YJ, Huang L, Zhang TF, Liu JY, Li F, Zhang Z, Yue DL, Wang F, Zhang B, Zhang Y*. Selective Depletion of Regulatory T Cell Subsets by Docetaxel Treatment in Patients with Nonsmall Cell Lung Cancer. J Immunol Res, 2014, 2014:286170.

20.Wang D, Li J, Liu JY, Li F, Wang LP, Huang L, Li JY, Chen XF, Liu JB, Wu CC, Yuan WT, Wang GX, Song JM, Yue DL, Zhang Z, Ping Y, Wang RR, Zhang JY, Zhang Y*. Modification of chemokine receptor expression to enhance levels of trafficking receptors on autologous cytokine-induced killer cells derived from patients with colorectal cancer. Biomed Pharmacother, 2014, 68(5):551-556.

21.Zhang Q*, Wang L, Luo C, Shi Z, Cheng X, Zhang Z, Yang Y, Zhang Y*. Phenotypic and functional characterization of cytokine-induced killer cells derived from preterm and term infant cord blood. Oncol Rep, 2014, 32(5):2244-2252.

22.Zhang J, Han S, Zhang B, Zhang Y. Cancer immunology and cancer immunodiagnosis. J Immunol Res, 2014, 2014:725691.

23.Chai Y, Peng B, Dai L, Qian W, Zhang Y, Zhang JY. Autoantibodies Response to MDM2 and p53 in the Immunodiagnosis of Esophageal Squamous Cell Carcinoma. Scand J Immunol, 2014, 80(5):362-368.

24.Zou Y, Li F, Hou W, Sampath P, Zhang Y, Thorne SH. Manipulating the expression of chemokine receptors enhances delivery and activity of cytokine-induced killer cells. Br J Cancer, 2014, 110(8):1992-1999.

25.Liu X, Ye H, Li L, Li W, Zhang Y, Zhang J. Humoral Autoimmune Responses to Insulin-Like Growth Factor II mRNA-Binding Proteins IMP1 and p62/IMP2 in Ovarian Cancer. J Immul Res, 2014, 2014:326593.

26.Jia R, Guo R, Liu G, Yuan X, Dong C, Shan T, Yuan X, Zhang Y, Tai EW, Feng X, Gao S. Evaluation of combined Argon Plasma Coagulation and Savary bougienage for the relief of anastomotic-stenosis after esophageal squamous cancer surgery. Dig Surg, 2014;31(6):415-21.

27.Xie Y, Wang JL, Ji M, Yuan ZF, Peng Z, Zhang Y, Wen JG, Shi HR. Regulation of insulin-like growth factor signaling by metformin in endometrial cancer cells. Oncol Lett, 2014, 8(5):1993-1999.

28.Wang P, Song C, Xie W, Ye H, Wang K, Dai L, Zhang Y, Zhang J. Evaluation of Diagnostic Value in Using a Panel of Multiple Tumor-Associated Antigens for Immunodiagnosis of Cancer. J Immul Res, 2014, 2014:512540.

29.Han L, Liu F, Li R, Li Z, Chen X, Zhou Z, Zhang X, Hu T, Zhang Y, Young K, Sun S, Wen J, Zhang M. Role of programmed death ligands in effective T-cell interactions in extranodal natural killer/T-cell lymphoma. Oncol Lett, 2014, 8(4):1461-1469.

30.Wang M, Zheng W, Zhang H, Li Z, Jiang D, Liu Y, Zhou R, Li XG, Zhang Y, Zhang Z, Wu S, Zhang Y, Li J. Short-term curative effect of ribavirin combination therapy with pegylated interferon alfa-2a vs. interferon alfa-2a in patients with chronic hepatitis C. Zhonghua Gan Zang Bing Za Zhi, 2014, 22(4):255-259. Article in Chinese.

31.Liu HC, Zhang Y, Wang XL, Qin WS, Liu YH, Zhang L, Zhu CL. Upregulation of the TPX2 gene is associated with enhanced tumor malignance of esophageal squamou cell cacinoma. Biomed Pharmacother, 2013, 67(8):751-755.

32.Wang L, Fan J, Chen S, Zhang Y, Curiel TJ, Zhang B. Graft-versus-host disease is enhanced by selective CD73 blockade in mice. Plos One, 2013, 8(3):e58397.

33.Han L, Zhang X, Geng L, Li M, Zhang Y, Wu MX. The expression of immediate early response gene X-1 in preeclampsia placenta and its pro-apoptotic role in preelampsia. Hypertens Pregnancy, 2013, 32(2):157-168.

34.Qin J, Song B, Zhang H, Wang Y, Wang N, Ji Y, Qi J, Chandra A, Yang B, Zhang Y, Gong G, Xu Y. Transplantation of human neuro-epithelial-like stem cells derived from induced pluripotent stem cells improves neurological function in rats with experimental intracerebral hemorrhage. Neurosci Lett, 2013, 548:95-100.

35.Qin J, Gong G, Sun S, Qi J, Zhang H, Wang Y, Wang N, Wang QM, Ji Y, Gao Y, Shi C, Yang B, Zhang Y, Song B, Xu Y. Functional recovery after transplantation of induced pluripotent stem cells in a rat hemorrhagic stroke model. Neurosci Lett, 2013, 554:70-75.

36.Li ZQ, Zhang Y*, Li Q, Wu SH, Sun CY, Yu ZJ. Alteration of renal cyclooxygenase expression due to partial unilateral ureteral obstruction in neonatal. Can Urol Assoc J, 2012,7(3): E150-E155.

37.Wang L, Fan J, Thompson LF, Zhang Y, Shin T, Curiel TJ, Zhang B. CD73 has distinct roles in nonhematopoietic and hematopoietic cells to promote tumor growth in mice. J Clin Invest,2011,121(6):2371-82.

38.Zhang Y, Liu Y, Moxley KM, Golden-Mason L, Hughes MG, Liu T, Heemskerk MH, Rosen HR, Nishimura MI. Transduction of Human T Cells with a Novel T-Cell Receptor Confers Anti-HCV Reactivity. Plos Pathogen, 2010, 6(7): e1001018.

39.Norell H, Zhang Y, McCracken J, Martins da Palma T, Lesher A, Liu Y, Roszkowski JJ, Temple A, Callender GG, Clay T, Orentas R, Guevara-Patiño J, Nishimura MI. CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting. Cancer Immunol Immunother, 2010, 59:851-862.

40.Zhang B, Zhang Y, Bowerman NA, Schietinger A, Fu YX, Kranz DM, Rowley DA, Schreiber H. Equilibrium between host and cancer caused by effector T cells killing tumor stroma. Cancer Res, 2008, 68:1563-1571.

41.Sun Z, Lethé B, Zhang Y, Russo V, Colau D, Stroobant V, Boon T, van der Bruggen P. A new LAGE-1 peptide recognized by cytolytic T lymphocytes on HLA-A68 tumors. Cancer Immunol Immunother, 2006,55(6):644-652.

42.Zhang Y, Sun Z, Nicolay H, Meyer RG, Renkvist N, Stroobant V, Corthals J, Carrasco J, Eggermont AM, Marchand M, Thielemans K, Wölfel T, Boon T, van der Bruggen P. Monitoring of anti-vaccine CD4 T cell frequencies in melanoma patients vaccinated with a MAGE-3 protein. J Immunol,2005, 174(4): 2404-2411.

43.Zhang Y, Renkvist N, Sun Z, Schuler-Thurner B, Glaichenhaus N, Schuler G, Boon T, van der Bruggen P, Colau D. A polyclonal anti-vaccine CD4 T cell response detected with HLA-DP4 multimers in a melanoma patient vaccinated with MAGE-3.DP4-peptide-pulsed dendritic cells. Eur J Immunol, 2005, 35(4):1066-1075.

44.Ottaviani S, Zhang Y, Boon T, van der Bruggen P. A MAGE-1 antigenic peptide recognized by human cytolytic T lymphocytes on HLA-A2 tumor cells. Cancer Immunol Immunother, 2005, 54(12):1214-1220.

45.Kruit WH, van Ojik HH, Brichard VG, Escudier B, Dorval T, Dréno B, Patel P, van Baren N, Avril MF, Piperno S, Khammari A, Stas M, Ritter G, Lethé B, Godelaine D, Brasseur F, Zhang Y, van der Bruggen P, Boon T, Eggermont AM, Marchand M. Phase 1/2 study of subcutaneous and intradermal immunization with a recombinant MAGE-3 protein in patients with detectable metastatic melanoma. Int J Cancer, 2005, 117(4):596-604 .

46.Bonehill A, Heirman C, Tuyaerts S, Michiels A, Breckpot K, Brasseur F, Zhang Y, Van Der Bruggen P, Thielemans K. Messenger RNA-Electroporated Dendritic Cells Presenting MAGE-A3 Simultaneously in HLA Class I and Class II Molecules. J Immunol, 2004 Jun 1; 172(11): 6649–6657.

47.Zhang Y, Chaux P, Stroobant V, Eggermont AM, Corthals J, Maillère B, Thielemans K, Marchand M, Boon T, Van Der Bruggen P. A MAGE-3 peptide presented by HLA-DR1 to CD4+ T cells that were isolated from a melanoma patient vaccinated with a MAGE-3 protein. J Immunol, 2003, 171(1):219-225.

48.Bonehill A, Heirman C, Tuyaerts S, Michiels A, Zhang Y, van der Bruggen P, Thielemans K. Efficient Presentation of Known HLA Class II-restricted MAGE-A3 Epitopes by Dendritic Cells Electroporated with Messenger RNA Encoding an Invariant Chain with Genetic Exchange of Class II-associated Invariant Chain Peptide. Cancer Res, 2003, 63(17):5587-5594.

49.Zhang Y, Stroobant V, Russo V, Boon T, van der Bruggen P. A MAGE-A4 peptide presented by HLA-B37 is recognized on human tumors by cytolytic T lymphocytes. Tissue Antigens, 2002, 60(5):365-371.

50.Van Der Bruggen P, Zhang Y, Chaux P, Stroobant V, Panichelli C, Schultz ES, Chapiro J, Van Den Eynde BJ, Brasseur F, Boon T. Tumor-specific shared antigenic peptides recognized by human T cells. Immunol Rev, 2002, 188:51-64.

51.Schultz ES, Zhang Y, Knowles R, Tine J, Traversari C, Boon T, van der Bruggen P. A MAGE-3 peptide recognized on HLA-B35 and HLA-A1 by cytolytic T lymphocytes. Tissue Antigens, 2001, 57(2):103-109.

52.Cheng JL, Liu BL, Zhang Y, Tong WB, Yan Z, Feng BF. Hepatitis C virus in human B lymphocytes transformed by Epstein-Barr virus in vitroby in situ reverse transcriptase-polymerase chain reaction. World J Gastroentero, 2001, 7(3):370-375.

53.刘金燕, 李峰, 陈新峰, 王丽萍, 岳冬丽, 赵松, 胡伟, Pawel Kalinski, Stephen Thorne, Jingzhou Hou, 张毅*. 趋化因子CCL5在食管癌患者中的表达及意义. 中华肿瘤学杂志, 2014, 36(11):828-833.

54.李志勤, 王盟, 王菲, 张震, 黄建敏, 李建斌, 程计林, 张毅*. 人类白细胞抗原-A2表型在不同基因型丙型肝炎病毒感染者中的表达差异及其临床意义. 中华传染病杂志, 2014, 32(6): 364-367.

55.高群, 王菲, 王丽萍, 杨黎, 张震, 岳冬丽, 王盟, 张毅*. 不同培养基与血清的培养体系对细胞因子诱导杀伤细胞增殖和功能的影响. 中国肿瘤生物治疗杂志, 2014, 21(6):680-686.

56.王海楠, 齐源明, 高岩峰, 周哲俊, 李志勤, 杜军波, 李建斌, 张毅*. 河南省肿瘤、慢性丙型肝炎、白癜风患者HLA-A2的分布. 郑州大学学报：医学版, 2014, 49(1): 11-14.

57.王菲, 王丽萍, 张震, 岳冬丽, 段秀芳, 张斌, 张毅*. 冻存对细胞因子诱导的杀伤细胞免疫表型及细胞内因子表达的影响. 郑州大学学报：医学版, 2014, 49(1): 11-14.

58.段秀芳, 王丽萍, 许钰杰, 邝先奎, 王菲, 王盟, 张斌, 张毅*. 晚期肺癌患者化疗前后血浆转化生长因子β1水平变化. 郑州大学学报：医学版. 2014, 49(1): 21-24.

59.谭丽霞, 李建生*, Dige Andom, 王丽萍, 张毅*. 食管鳞状细胞癌组织中PD-1、CD45 RO 和 OX40的表达. 郑州大学学报：医学版, 2014, 49(2): 141-145.

60.李静, 王菲, 刘艳芬, 王丽萍, 许钰杰, 王盟, 张斌, 张毅*. 不同刺激物对细胞因子诱导的杀伤细胞分泌细胞因子的影响. 郑州大学学报：医学版. 2014, 49(2): 166-168.

61.岳冬丽, 韩交玲, 关方霞, 张毅*. 肿瘤干细胞的研究进展及临床意义. 郑州大学学报(医学版), 2013, 48(1):1-8.

62.白晶, 李爱军*, 王丽萍, 张斌, 张毅*. 浆液性卵巢癌组织中 CD44和 CD24的表达. 郑州大学学报（医学版）, 2013, 48(6):729-732.

63.张震, 赵先兰, 王丽萍, 杨玲竹, 杨黎, 张斌, 张毅*. 脐血来源CIK细胞高表达激活型表面标志物及耐药基因ABCG2. 中国肿瘤生物治疗杂志, 2013, 20(1):20-25.

64.李志勤, 孙长宇, 余祖江, 黄建敏, 李建生*, 张毅*. HCV核心蛋白对人肝癌细胞系SMMC-7721增殖的影响. 郑州大学学报(医学版), 2013, 48(3):310-313.

65.李志勤, 王菲, 张震, 王盟, 黄建敏, 李建生*, 张毅*. 不同临床类型HCV感染者外周血CD4+CD25+调节性T细胞分布比例. 郑州大学学报(医学版), 2013, 48(2):232-234.

66.宋东建, 张毅, 王磊, 刘秋亮, 岳丽芳, 张大, 徐彦磊, 高鹏飞, 王家祥. p73基因在肾母细胞瘤组织中的表达及甲基化相关性研究. 中华实用儿科临床杂志, 2013, 28(11):823-827.

67.许钰杰, 张毅, 邝先奎, 段秀芳, 李洁瑶, 李建斌, 张震, 张斌, 王丽萍. 肺癌患者化疗前后T细胞抑制性分子的研究. 中国肿瘤临床, 2013, 40(16):960-964.

68.韩丽萍, 张晓雪, 张毅, 耿丽娜, 李萌萌. IEX-1基因转染对人卵巢癌细胞增殖活性及顺铂敏感性的影响. 中国妇幼保健, 2013, 28(14):2297-2299.

69.杨黎, 姬少绯, 朱振宇, 张毅. 肝细胞癌中Survivin mRNA和Survivin-△Ex3 mRNA的表达及临床意义研究. 肿瘤防治研究, 2013, 40(12): 1147-1150.

70.王义生, 左松, 荆凯, 张毅, 李月白. 激素对人骨髓间充质干细胞凋亡及神经肽受体基因表达的影响. 中华实验外科杂志, 2013, 30(3):602-604.

71.李留霞, 李秀芳, 张兰兰, 张毅. 子痫前期患者血浆对人脐静脉内皮细胞增殖及Edg4表达的影响. 郑州大学学报(医学版), 2013, 48(1):96-99.

72.李留霞, 李秀芳, 张兰兰, 张毅, 郭瑞霞, 张孝艳, 周艳, 乔玉环, 苏克. 子痫前期孕妇血浆对人脐静脉内皮细胞增殖和凋亡的影响及其与溶血磷脂酸受体的关系. 中华妇产科杂志, 2013, 48(2):102-106.

73.杨威, 郑丽丽, 李冲, 李珊, 王志芳, 王小红, 张毅. 艾塞那肽抑制高糖诱导内皮细胞凋亡的作用机制. 中华内分泌代谢杂志, 2013, 29(9):809-811.

74.李留霞, 张兰兰, 李秀芳, 张建营, 王凯娟, 代丽萍, 王鹏, 张毅. 六种肿瘤相关抗原自身抗体联合CA125检测对卵巢癌早期诊断的价值. 郑州大学学报(医学版), 2013, 48(2):238-242.

75.杜军波, 于建斌*, 黄建敏, 张江安, 苗青, 张斌, 张毅*. 白癜风患者外周血T淋巴细胞CD28、CTLA-4的表达. 郑州大学学报(医学版), 2012, 47(6):776-778.

76.程计林, 王立巍, 邱趁丽, 艾迎春, 陆基华, 殷科珊, 黄绍萍, 唐荣, 徐烈, 张毅*. 乙型肝炎相关肝癌患者乙型肝炎病毒不同抗原肽特异性CD3+CD8+人白细胞抗原-A2+细胞表达. 中华传染病杂志, 2012, 30(5):264-267.

77.徐彦磊, 王家祥, 张毅, 杨合英, 樊玉霞, 宋东建, 乔永涛. 肾母细胞瘤中ABCG2的表达及侧群的检测. 中华小儿外科杂志, 2012, 33(9):665-668.

78.李留霞, 吴改英, 王宁, 张毅, 郭瑞霞, 张孝艳. 子痫前期患者胎盘组织中内皮分化基因2的表达. 郑州大学学报(医学版), 2012, 47(4):497-499.

79.李留霞, 李秀芳, 张兰兰, 张毅. 子痫前期患者血浆对人脐静脉内皮细胞生长活性及Edg4表达的影响. 现代妇产科进展, 2012, 21(10):775-778.

80.李留霞, 吴改英, 王宁, 张毅, 郭瑞霞, 张孝艳. 子痫前期孕妇胎盘组织中内皮分化基因2的表达. 中华妇产科杂志, 2012, 47(6):463-464.

81.张毅*, Michael Nishimura. 肿瘤的细胞免疫治疗. 郑州大学学报(医学版), 2011, 46(2):165-169.

82.杨双宁,王丽萍*,张毅*. 肺癌免疫治疗现状. 肿瘤基础与临床, 2010, 23(5):456-460.

83.Sun J, Chen H, Zhang Y, Wang Y. The function of cytokines and anti-CD3 on the activation of peripheral blood mononuclear cells. Journal of Chinese Microbiology and Immunology. 2002, 22: 321

84.Sun J, Chen H, Gao Y, Wang S, Zhang Y, Wang Y. Comparison of Serum2Free Medium AIMV with Standard Serum2ContainingMedium in Culturing Cells Activated with IFN-, IL22 and Anti-CD3. Chinese Journal of Cancer Biotherapy. 2001, 8:208.

85.Cheng J, Sun X, Zhang Y. Study on the persistent existence of HCV II type in EBV transformed PBMC. J of Beijing Medical University. 2000, 1: 38.

86.Guo Q, Cui L, Zhang Y. Observation of treatment on patients with HBV infection with three combined drugs. Journal of Henan Preventive Medicine. 1999. 10: 94.

87.Cui L, Zhang M, Zhang Y. Treatment on the 78 cases with chronic Hepatitis B by BV vaccine combined with traditional Chinese medicine. Chinese Journal of Integrated Traditional and Western Medicine on Liver Diseases, 1999, 9: 328, 1999.

88.Zhang M, Cui L, Zhang Y. Effective analysis of 90 cases with chronic Hepatitis B treated by anti-HBV specific immune factor. Journal of Henan Medical University, 1999, 34: 88.

89.Guo Q, Cui L, Zhang Y. Study on effective of three drugs treatment 135 cases with HBV carrier. Journal of Preventive Medicine, 1999, 10: 94.

专著：

参编《生物治疗中的转化医学》，第四军医大学出版社，ISBN：9787566206077，出版时间：2014-11-01。

所获专利：

1.MAGE peptides presented by HLA class II molecules, 美国, US 7 388 072 B2；

2.一种鉴定恶性胸腔积液的方法, 中国, 201310720677.8。

所获奖励：

1.河南省特聘教授，授予机构：河南省人民政府，2009；

2.河南省科技创新杰出人才，丙肝相关肝癌T细胞受体基因治疗的研究，授予机构：河南省科学技术厅，2012；

3.优秀中青年科技创新人才；授予机构：河南省卫生厅，2012；

4.河南省卫生科技创新型人才工程中青年科技创新人才，授予机构：河南省卫生厅，，2010；

5.第五届全国生物治疗学术大会优秀论文一等奖，授予机构：中国医药生物技术协会医药生物技术临床应用专业委员会，2010。